Verition Fund Management LLC Intercept Pharmaceuticals, Inc. Transaction History

Verition Fund Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$9.99 - $18.71 $370,009 - $692,980	-37,038 Reduced 76.4%	11,439 $212,000
Q2 2023 Aug 14, 2023	BUY	$9.17 - $19.29 $331,853 - $698,085	36,189 Added 294.51%	48,477 $536,000
Q1 2023 May 15, 2023	BUY	$12.53 - $21.71 $11,715 - $20,298	935 Added 8.24%	12,288 $165,000
Q4 2022 Feb 14, 2023	SELL	$11.61 - $16.11 $198,147 - $274,949	-17,067 Reduced 60.05%	11,353 $140,000
Q3 2022 Nov 14, 2022	BUY	$12.21 - $19.7 $165,762 - $267,447	13,576 Added 91.46%	28,420 $396,000
Q2 2022 Aug 15, 2022	BUY	$11.23 - $19.59 $166,698 - $290,793	14,844 New	14,844 $205,000
Q2 2021 Aug 16, 2021	SELL	$15.46 - $24.5 $192,198 - $304,584	-12,432 Closed	0 $0
Q1 2021 May 18, 2021	BUY	$19.33 - $37.75 $240,310 - $469,308	12,432 New	12,432 $286,000
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $151,889 - $208,230	-2,588 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$77.77 - $120.68 $201,268 - $312,319	2,588 New	2,588 $206,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.